Clinical Preventive Service Recommendation

Cardiovascular Disease

Cardiovascular Disease, Aspirin for Prevention in Men 45 to 79

The AAFP recommends the use of aspirin for men age 45 to 79 years when the potential benefit due to a reduction in myocardial infarctions outweighs the potential harm due to an increase in gastrointestinal hemorrhage. (2009)

(Grade: A recommendation)
Grade Definition: http://www.uspreventiveservicestaskforce.org/uspstf/grades.htm(www.uspreventiveservicestaskforce.org)
Clinical Considerations: http://www.uspreventiveservicestaskforce.org/uspstf/uspsasmi.htm(www.uspreventiveservicestaskforce.org)

Cardiovascular Disease, Aspirin for Prevention in Women 55 to 79

The AAFP recommends the use of aspirin for women age 55 to 79 years when the potential benefit of a reduction in ischemic strokes outweighs the potential harm of an increase in gastrointestinal hemorrhage. (2009)

(Grade: A recommendation)
Grade Definition: http://www.uspreventiveservicestaskforce.org/uspstf/grades.htm(www.uspreventiveservicestaskforce.org)
Clinical Considerations: http://www.uspreventiveservicestaskforce.org/uspstf/uspsasmi.htm(www.uspreventiveservicestaskforce.org)

Cardiovascular Disease, Aspirin for Prevention in Adults younger than 45

The AAFP recommends against the use of aspirin for stroke prevention in women younger than 55 years and for myocardial infarction prevention in men younger than 45 years. (2009)

(Grade: D recommendation)
Grade Definition: http://www.uspreventiveservicestaskforce.org/uspstf/grades.htm(www.uspreventiveservicestaskforce.org)
Clinical Considerations: http://www.uspreventiveservicestaskforce.org/uspstf/uspsasmi.htm(www.uspreventiveservicestaskforce.org)

Cardiovascular Disease, Aspirin for Prevention in Adults 80 years or older

The AAFP concludes that the evidence is insufficient to assess the benefits and harms of aspirin for cardiovascular disease prevention in men and women 80 years or older. (2009)

(Grade: I recommendation)
Grade Definition: http://www.uspreventiveservicestaskforce.org/uspstf/grades.htm(www.uspreventiveservicestaskforce.org)
Clinical Considerations: http://www.uspreventiveservicestaskforce.org/uspstf/uspsasmi.htm(www.uspreventiveservicestaskforce.org)

Cardiovascular Disease, Genomic Testing

The AAFP recommends against genomics profiling to assess risk for cardiovascular disease. The net health benefit from the use of any genomic tests for the assessment of cardiovascular disease risk is negligible and there is no evidence that they lead to improved patient management or increased risk reduction. (2012)

Clinical Consideration: http://www.nature.com/gim/journal/v12/n12/pdf/gim2010136a.pdf(www.nature.com)


These recommendations are provided only as assistance for physicians making clinical decisions regarding the care of their patients. As such, they cannot substitute for the individual judgment brought to each clinical situation by the patient's family physician. As with all clinical reference resources, they reflect the best understanding of the science of medicine at the time of publication, but they should be used with the clear understanding that continued research may result in new knowledge and recommendations. These recommendations are only one element in the complex process of improving the health of America. To be effective, the recommendations must be implemented.